Avanos Medical Shares Surge on $1.27 Billion AIP Buyout Offer
AI-generated from multiple sources. Verify before acting on this reporting.
NEW YORK — Shares of Avanos Medical Inc. climbed sharply Monday after AIP announced a definitive agreement to acquire the medical device manufacturer in an all-cash transaction valued at $1.27 billion. The deal, announced late Monday afternoon, represents a significant premium over Avanos' closing price prior to the news, sending the stock into a trading frenzy on U.S. exchanges.
AIP, a private equity firm, proposed to pay $38.50 per share for Avanos Medical, a company specializing in urology and vascular care products. The acquisition marks one of the largest buyouts in the medical technology sector this year. Avanos Medical's board of directors unanimously recommended the transaction to shareholders, citing the immediate liquidity and value it provides to investors.
The agreement is subject to regulatory approval and shareholder ratification. AIP expects to close the transaction by the end of the third quarter of 2026, pending customary closing conditions. The deal structure includes a cash payment for all outstanding shares, with no stock component involved. Avanos Medical will be delisted from the NASDAQ upon completion of the merger.
Industry analysts noted the strategic rationale behind the acquisition, pointing to Avanos' strong portfolio of catheter and ostomy products. The company has faced pressure from rising input costs and supply chain disruptions over the past two years, which may have influenced the decision to sell. AIP has a history of investing in healthcare infrastructure and has previously acquired several mid-sized medical device firms to consolidate market share.
Avanos Medical's CEO stated in a press release that the transaction provides a compelling opportunity for shareholders to realize value in a challenging market environment. The company's management team will remain in place during the transition period, ensuring operational continuity for customers and employees. No immediate changes to Avanos' product lines or manufacturing facilities are expected.
The stock market reaction was immediate. Avanos Medical shares jumped more than 25% in after-hours trading following the announcement. Trading volume was significantly higher than the daily average, reflecting investor enthusiasm for the deal. Some analysts cautioned that regulatory hurdles could delay the closing, particularly given increased scrutiny of healthcare acquisitions by federal authorities.
Questions remain regarding the timeline for regulatory clearance and whether competing bids might emerge. AIP has included a breakup fee in the agreement to deter other potential buyers. The company has not disclosed the source of funding for the transaction, though it is believed to be backed by a consortium of institutional investors. Shareholders will vote on the proposal at a special meeting scheduled for next month.
As the deal moves forward, attention will focus on whether AIP can secure the necessary approvals without triggering antitrust concerns. The medical device sector has seen a wave of consolidation in recent years, with larger firms seeking to expand their reach through acquisitions. Avanos Medical's integration into AIP's portfolio could reshape the competitive landscape for urology and vascular care products in the United States.